Quick Answer
Cellectar Biosciences, Inc. reported Stockholders Equity of $8.54 million for the year ending 2025.
- Cellectar Biosciences, Inc. showed a decrease of -40.3% in Stockholders Equity from 2024 to 2025.
- This data is from Cellectar Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $2.58 million | Q2 2016: $9.83 million | Q3 2016: $7.72 million | Q1 2017: $13.75 million | Q2 2017: $10.86 million | Q3 2017: $7.59 million | Q1 2018: $7.45 million | Q2 2018: $4.71 million | Q3 2018: $16.88 million | Q1 2019: $9.85 million | Q2 2019: $15.99 million | Q3 2019: $12.23 million | Q1 2020: $5.25 million | Q2 2020: $19.99 million | Q3 2020: $16.22 million | Q1 2021: $49.78 million | Q2 2021: $43.98 million | Q3 2021: $38.59 million | Q1 2022: $27.21 million | Q2 2022: $20.19 million | Q3 2022: $12.75 million | Q1 2023: $1.37 million | Q2 2023: -$8.39 million | Q3 2023: -$28.00 million | Q1 2024: $12.50 million | Q2 2024: $12.38 million | Q3 2024: $15.16 million | Q1 2025: $8.25 million | Q2 2025: $6.09 million | Q3 2025: $8.00 million.
- Over the full 18 years of available data (2008 to 2025), Cellectar Biosciences, Inc.'s Stockholders Equity has declined by 13.3%.
- Historical annual values: Fiscal year 2025: $8.54 million | Fiscal year 2024: $14.29 million | Fiscal year 2023: -$15.16 million | Fiscal year 2022: $8.15 million | Fiscal year 2021: $33.05 million | Fiscal year 2020: $54.79 million | Fiscal year 2019: $9.06 million | Fiscal year 2018: $13.26 million | Fiscal year 2017: $10.75 million | Fiscal year 2016: $13.54 million | Fiscal year 2015: $1.65 million | Fiscal year 2014: $6.70 million | Fiscal year 2013: $1.70 million | Fiscal year 2012: $10.16 million | Fiscal year 2011: $9.48 million | Fiscal year 2010: $133.8 thousand | Fiscal year 2009: $4.13 million | Fiscal year 2008: $9.84 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: